Newspaper clipping of Unaudited Financial Results of Quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals Ltd has submitted to BSE the newspaper clipping containing its standalone unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). The submission was made on August 7, 2025, in line with SEBI's Listing Obligations and Disclosure Requirements, 2015. The company advertised the quarterly results in a newspaper and is sharing that clipping with the exchange as a compliance formality. Signed by Chintan Didawala Ganpat, Managing Director & CFO. The detailed line items in the embedded financial table are not legibly readable in the submitted text, so specific revenue, expense, and profit numbers cannot be confirmed from this filing.
This is a routine regulatory compliance submission and does not by itself indicate any new business development. Shareholders should look to the company's separately filed detailed Q1 results for actual performance numbers and any impact on the stock.